These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 33208635)

  • 1. Effects of Antibiotic Use on Outcomes in Cancer Patients Treated Using Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Yu Y; Zheng P; Gao L; Li H; Tao P; Wang D; Ding F; Shi Q; Chen H
    J Immunother; 2021 Feb-Mar 01; 44(2):76-85. PubMed ID: 33208635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Chen H; Han KD; He ZJ; Huang YS
    Technol Cancer Res Treat; 2021; 20():15330338211033498. PubMed ID: 34323149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors.
    Zhou J; Huang G; Wong WC; Hu DH; Zhu JW; Li R; Zhou H
    Front Immunol; 2022; 13():968729. PubMed ID: 35967438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic administration shortly before or after immunotherapy initiation is correlated with poor prognosis in solid cancer patients: An up-to-date systematic review and meta-analysis.
    Yang M; Wang Y; Yuan M; Tao M; Kong C; Li H; Tong J; Zhu H; Yan X
    Int Immunopharmacol; 2020 Nov; 88():106876. PubMed ID: 32799113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
    Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors.
    Giordan Q; Salleron J; Vallance C; Moriana C; Clement-Duchene C
    Front Immunol; 2021; 12():716317. PubMed ID: 34777340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of antibiotics on efficacy of immune checkpoint inhibitors in malignancies: A study based on 44 cohorts.
    Wu Q; Liu J; Wu S; Xie X
    Int Immunopharmacol; 2021 Mar; 92():107303. PubMed ID: 33465728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of antibiotic use and other concomitant medications on the efficacy of immune checkpoint inhibitors in patients with advanced cancer.
    Iglesias-Santamaría A
    Clin Transl Oncol; 2020 Sep; 22(9):1481-1490. PubMed ID: 31919759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer.
    Pinato DJ; Howlett S; Ottaviani D; Urus H; Patel A; Mineo T; Brock C; Power D; Hatcher O; Falconer A; Ingle M; Brown A; Gujral D; Partridge S; Sarwar N; Gonzalez M; Bendle M; Lewanski C; Newsom-Davis T; Allara E; Bower M
    JAMA Oncol; 2019 Dec; 5(12):1774-1778. PubMed ID: 31513236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non-small cell lung cancer (AB-CLICaP).
    Ruiz-Patiño A; Barrón F; Cardona AF; Corrales L; Mas L; Martín C; Zatarain-Barrón ZL; Recondo G; Ricaurte L; Rojas L; Archila P; Rodríguez J; Sotelo C; Viola L; Vargas C; Carranza H; Otero J; Pino LE; Rolfo C; Rosell R; Arrieta O;
    Thorac Cancer; 2020 Sep; 11(9):2552-2560. PubMed ID: 32705787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibiotic use reduces the efficacy of immune checkpoint inhibitors in patients with urothelial carcinoma: A systematic review and meta-analysis.
    Febriyanto T; Muhammad F; Wijaya W; Oey O; Simadibrata DM
    Urol Oncol; 2024 May; 42(5):160.e11-160.e23. PubMed ID: 38101990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of antibiotic treatment on immune checkpoint inhibitors efficacy in patients with advanced non-small cell lung cancer.
    Alkan Şen G; Şentürk Öztaş N; Değerli E; Can G; Turna H; Özgüroğlu M
    Lung Cancer; 2023 Oct; 184():107347. PubMed ID: 37597304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-PD-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis.
    Park R; Lopes L; Saeed A
    Clin Transl Oncol; 2021 Jan; 23(1):100-109. PubMed ID: 32495269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis.
    Lopes S; Pabst L; Dory A; Klotz M; Gourieux B; Michel B; Mascaux C
    Front Immunol; 2023; 14():1070076. PubMed ID: 36776847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of antibiotic exposure with survival in patients with extensive-stage small cell lung cancer receiving immune checkpoint inhibitor therapy.
    Zhong J; Xiong D; Liu Y; Yuan S
    Thorac Cancer; 2024 Jan; 15(2):152-162. PubMed ID: 38010059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma.
    Pinato DJ; Li X; Mishra-Kalyani P; D'Alessio A; Fulgenzi CAM; Scheiner B; Pinter M; Wei G; Schneider J; Rivera DR; Pazdur R; Theoret MR; Casak S; Lemery S; Fashoyin-Aje L; Cortellini A; Pelosof L
    JHEP Rep; 2023 Jun; 5(6):100747. PubMed ID: 37197442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis.
    Kok PS; Cho D; Yoon WH; Ritchie G; Marschner I; Lord S; Friedlander M; Simes J; Lee CK
    JAMA Netw Open; 2020 Sep; 3(9):e2011809. PubMed ID: 32897371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
    Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
    Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The negative effect of antibiotics on RCC patients with immunotherapy: A systematic review and meta-analysis.
    Luo Z; Hao S; Li Y; Cheng L; Zhou X; Gunes EG; Liu S; Chen J
    Front Immunol; 2022; 13():1065004. PubMed ID: 36505435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.